Skip to main content

Advertisement

Table 2 Clinical and ultrasound parameters at baseline and after 12 months in total population, group of responders and non-responders

From: Fluorescence optical imaging for treatment monitoring in patients with early and active rheumatoid arthritis in a 1-year follow-up period

  Month of visit 0 (V0)* Month of visit 12 (V12)* Difference between V12 and V0* p value (Wilcoxon signed rank test)
Total population (n = 35 for clinical, n = 34 for US7 parameters)
 28-SJC 5 (3;9.5) (1;20) 1 (0;2) (0;10) −4 (−7;− 1) (−19;3) < 0.001 (sig.)
 28-TJC 7 (3.5;15) (1;25) 1 (0;3) (0;26) −4 (− 10;− 1) (−24;6) < 0.001 (sig.)
 DAS28(ESR) 5.61 (4.8;6.23) (3.55;7.57) 3.31 (2.45;3.98) (1.13;6.19) −2.22 (−3.11;− 1.39) (−5.45;0.56) < 0.001 (sig.)
 GS-synovitis 7 (5.5;9.5) (2;15) 6 (4.25;7) (2;10) − 1 (−3;0) (−9;7) 0.0112 (sig.)
 GS-tenosynovitis 3 (2;4) (0;5) 2.5 (2;3) (0;4) −0.5 (−1.75;0) (−4;2) 0.0239 (sig.)
 PD-synovitis 4 (3;7) (2;15) 3 (2;3.75) (0;11) −1 (−3;0) (−9;1) 0.00004 (sig.)
 PD-tenosynovitis 3 (2;4) (0;7) 2 (1.25;3) (0;5) 0 (−2;0.75) (−4;1) 0.0163 (sig.)
Group of responders (n = 16)
 28-SJC 3.5 (1.75;8.25) (1;15) 0 (0;1) (0;3) −3.5 (−8.25;− 1) (−14;1) 0.002 (sig.)
 28-TJC 4.5 (3;10.5) (1;24) 0 (0;0.25) (0;2) −3.5 (−10.5;− 3) (−24;− 1) < 0.001 (sig.)
 DAS28(ESR) 4.88 (4.33;6.18) (3.55;7.33) 2.38 (1.89;2.68) (1.13;3.18) −2.82 (−3.82;− 1.82) (−5.45;− 1.14) < 0.001 (sig.)
 GS-synovitis 8 (6;9.25) (2;12) 6 (4;7) (3;9) −2 (−4.25;0) (−9;7) 0.038 (sig.)
 GS-tenosynovitis 4 (2.75;5) (1;5) 2.5 (2;3) (1;4) −1 (−2;0) (−4;2) 0.0274 (sig.)
 PD-synovitis 4 (3.75;6.5) (2;11) 3 (2;3) (1;4) −2 (−5;− 0.75) (−8;1) 0.0028 (sig.)
 PD-tenosynovitis 3 (2;5) (1;7) 2 (2;3) (1;3) −1 (−2.25;0) (−4;1) 0.01 (sig.)
Group of non-responders (n = 19 for clinical, n = 18 for US7 parameters)
 28-SJC 6 (3.5;9.5) (1;20) 1 (0;4) (0;10) −5 (−6.5;− 2) (−19;3) 0.001 (sig.)
 28-TJC 11 (5.5;18.5) (1;25) 3 (1.5;11) (0;26) −4 (−8;0.5) (−22;6) 0.01 (sig.)
 DAS28(ESR) 5.82 (5.34;6.23) (3.61;7.57) 3.95 (3.51;5.21) (3.28;6.19) −1.62 (−2.61;− 0.51) (−3.73;0.56) < 0.001 (sig.)
 GS-synovitis 7 (4.5;9.5) (2;15) 6 (5;8.5) (2;10) −1 (−2;0.75) (−5;6) 0.1641
 GS-tenosynovitis 2 (2;4) (0;5) 2.5 (1;3) (0;4) 0 (−1;1) (−3;2) 0.506
 PD-synovitis 4 (2.5;7) (2;15) 3 (1;5) (0;11) −1 (−2;0) (−9;1) 0.0058 (sig.)
 PD-tenosynovitis 2 (1;3) (0;7) 2.5 (1;3) (0;5) 0 (−0.75;1) (−4;1) 0.7732
  1. Clinical and ultrasound (US) parameters at baseline and after 12 months in total population, group of responders and non-responders: *Median (1. quartile; 3. quartile); (min; max), significance level = 0.05; 28-SJC swollen joint count of 28 joints, 28-TJC tender joint count of 28 joints, DAS28(ESR) Disease Activity Score of 28 joints and erythrocyte sedimentation rate (ESR), GS greyscale mode in ultrasound, PD Power Doppler mode in ultrasound